Peginterferon beta-1a - Biocad

Drug Profile

Peginterferon beta-1a - Biocad

Alternative Names: BCD 054

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocad
  • Class Interferons; Neuroprotectants
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Multiple sclerosis

Most Recent Events

  • 10 Aug 2017 Phase-II/III clinical trials in Multiple sclerosis in Russia (IM) (NCT02744222)
  • 15 Apr 2016 Biocad plans a phase II trial for Multiple sclerosis in Russia (IM) (NCT02744222)
  • 01 Dec 2015 Biocad completes a phase I trial in Healthy volunteers in Russia (IM, SC) (NCT02359877)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top